Literature DB >> 7524743

Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID.

G E Tjønnfjord1, R Steen, O P Veiby, W Friedrich, T Egeland.   

Abstract

Severe combined immunodeficiencies (SCID), a heterogeneous group of disorders of infancy, are fatal without treatment directed at immunologic reconstitution. Allogeneic bone marrow transplantation (BMT), which is such a treatment presents some unique features in SCID, especially when T-lymphocyte-depleted HLA haploidentical allografts are used. Donor-type T lymphopoiesis, less often B lymphopoiesis, develops, whereas myelopoiesis remains the recipient-type. Little is known about the engrafting cells in this peculiar lymphohematopoietic chimerism and the pathophysiology of the frequent failure of B-lymphocyte reconstitution. To address these issues, we purified CD34+ BM cells from a patient with selective T-lymphocyte reconstitution after HLA haploidentical BMT for B-SCID. Phenotypic analysis of CD34+ cells was performed by flow cytometry, and functional studies of donor- and recipient-type CD34+ cells were performed in vitro. Donor-type CD34+ cells, constituting approximately 2% of the CD34+ cells, were detected; both CD34+ HLA-DR- cells and CD34+ cells coexpressing B-(CD10 and CD19) and T-(CD2 and CD7) lymphocyte-associated cell surface molecules. Donor-type CD34+ cells coexpressing myeloid-associated molecules (CD13, CD14, CD15, and CD33) were undetectable. However, donor-type CD34+ myeloid progenitors could be shown in functional assays. Recipient-type CD34+ cells coexpressing B- and T-lymphocyte- as well as myeloid-associated molecules were detected, but recipient-type CD34+ cells could not be driven into T-lymphocyte differentiation in vitro. These findings provide evidence for engraftment of multipotent stem cells in our patient with B-SCID. Furthermore, the failure of B-lymphocyte reconstitution cannot be explained by lack of donor-type B-lymphocyte progenitors. Donor-type B lymphopoiesis and myelopoiesis are prevented by an unidentified mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524743

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

Review 2.  Human artificial chromosomes for gene delivery and the development of animal models.

Authors:  Yasuhiro Kazuki; Mitsuo Oshimura
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

3.  Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.

Authors:  Denise A Carbonaro; Xiangyang Jin; Daniel Cotoi; Tiejuan Mi; Xiao-Jin Yu; Dianne C Skelton; Frederick Dorey; Rodney E Kellems; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2008-03-20       Impact factor: 22.113

4.  Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches.

Authors:  Agnieszka Czechowicz; Daniel Kraft; Irving L Weissman; Deepta Bhattacharya
Journal:  Science       Date:  2007-11-23       Impact factor: 47.728

5.  T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Authors:  D B Kohn; M S Hershfield; D Carbonaro; A Shigeoka; J Brooks; E M Smogorzewska; L W Barsky; R Chan; F Burotto; G Annett; J A Nolta; G Crooks; N Kapoor; M Elder; D Wara; T Bowen; E Madsen; F F Snyder; J Bastian; L Muul; R M Blaese; K Weinberg; R Parkman
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.